What It Is
BPC-157 is a synthetic 15-amino-acid peptide, or pentadecapeptide, based on a sequence originally studied in human gastric juice. It is also known in the literature as body protection compound 157, bepecin, or PL 14736.[1] Databases such as PubChem and NCATS Inxight Drugs list it as an investigational compound, not an approved medicine.
The peptide has attracted attention because it is unusually stable in water and gastric conditions compared to many other peptides, which made it a convenient tool for laboratory research into gut, tendon, and wound-healing biology. Stability in a test tube, however, says nothing about whether the compound works safely in humans.
How It Works
Unlike many peptide drugs, BPC-157 does not have one clearly identified receptor or signaling pathway. Published research instead points to several possible mechanisms, including modulation of nitric oxide signaling, promotion of new blood vessel formation (angiogenesis), and effects on fibroblast cell survival and migration.[4]
In laboratory tendon-cell studies, BPC-157 promoted cell outgrowth, survival under stress, and migration, likely through a signaling pathway involving proteins called FAK and paxillin.[5] These are broad, biologically plausible pathways involved in normal healing, but their breadth is also a limitation: because they touch so many normal processes, mechanistic activity in a dish or an animal does not translate cleanly into a predictable, targeted clinical effect in people.
What the Research Shows
The vast majority of BPC-157 evidence comes from animal and cell studies. Rat studies reported accelerated healing of surgically cut Achilles tendons, and separate rodent work examined gastric ulcers, colitis, and other gastrointestinal injury models.[3][7] A 2025 systematic review of BPC-157 in orthopedic sports medicine characterized the available evidence as mostly low-level, with limited human data.[21]
Human evidence is sparse and preliminary: a registered Phase 1 safety and pharmacokinetics trial in healthy volunteers, a small retrospective report on intra-articular use for knee pain, and a small 2024 pilot study in 12 women with interstitial cystitis reporting symptom improvement after a single intravesical treatment.[12][13][14] These early reports are hypothesis-generating, not proof of efficacy, and none involved the large, controlled, randomized design needed to establish a treatment effect.
Safety & Side Effects
A preclinical toxicology evaluation reported that BPC-157 was tolerated in animal models, and the small human pilot studies reported no adverse events in their narrow, closely monitored settings.[11][13][14] These reassuring signals come from very small sample sizes that are not designed to detect uncommon or delayed side effects, so they cannot stand in for a real human safety profile.
FDA has specifically flagged compounded BPC-157 products as a safety concern, citing:
- Possible immunogenicity (unwanted immune reactions)
- Peptide-related impurities from manufacturing
- Difficulty characterizing the active ingredient accurately
- Insufficient safety data for the routes commonly used in compounded products[16]
No data exist on use during pregnancy or breastfeeding, and drug interactions with anticoagulants, immune-modifying drugs, or cancer therapies are entirely uncharacterized.
Regulatory Status
BPC-157 is not an FDA-approved drug for any indication. FDA lists it among bulk substances that may present significant compounding safety risks and brought BPC-157-related substances to its Pharmacy Compounding Advisory Committee in July 2026.[16][18] The meeting materials state that an advisory recommendation is non-binding and that FDA's final determination follows its completed review; this page does not treat the meeting itself as an approval. No approved prescribing label, standard human dosage, or authoritative contraindication list exists.
Athletes face an additional, unambiguous restriction: the U.S. Anti-Doping Agency and the World Anti-Doping Agency list BPC-157 under the S0 "non-approved substances" category of the Prohibited List, meaning use carries anti-doping risk regardless of how the product is marketed.[19][20]